

Template Version	FDP National DPIA Template (Pseudo) version 1.1 240424		
Document filename	National Vaccination Programme Reporting – FDP National DPIA		
Directorate / Programme	FDP Programme	Product Name	National Vaccination Programme Reporting
Document Reference No	FDP 069N	Information Asset Register Number	[Insert]
Information Asset / Product Owner Name	[Insert]	Version	11.0 Final
Author(s)	[Redacted] (NECS Senior Consultant – Strategic Information Governance)	Version issue date	10/11/2025

**Redaction Rationale** – The information above for 'Information Asset/Product Owner' and 'Author(s)' has been redacted as this includes personal information, this has been completed in line with Section 40 (2) of the Freedom of Information Act 2000.

# FDP Product Data Protection Impact Assessment – National Vaccination Programme Reporting

# Document Management

## Revision History

Version	Date	Summary of Changes
0.1	19/06/2024	Information input into DPIA
0.2	10/07/2024	Update to DPIA to address DGG comments
0.3	26/07/2024	Review and comment on DPIA from GC
0.4	26/07/2024	Update and response to comments
0.5	26/07/2024	Clean version
0.6	01/08/2024	Update to DPIA with GC
0.7	01/08/2024	Clean version
1.0	02/08/2024	Finalisation of document
1.1	09/10/2024	Update to DPIA to reflect the ingestion of Maternity Datasets
2.0	15/10/2024	Clean updated DPIA
2.1	28/10/2024	Update to DPIA to include the creations of Aggregated Reports
3.0	28/10/2024	Clean final
4.0	20/11/2024	Update to DPIA to include invites to vaccines Data
4.1	27/11/2024	Update to include access to NHS National Booking Service
5.0	27/11/2024	Clean final version
5.1	18/02/2025	Update to DPIA to reference name change and updates
6.0	18/02/2025	Final Approved version
7.0	04/04/2025	Update to add the HPV dataset
7.1	15/05/2025	Update to document to clarify the content and inclusion of mapping school URNs to Local Authority
8.0	15/05/2025	Final Approved
8.1	28/05/2025	Update to include Ingress and Egress requests
9.0	28/05/2025	Final Updated Approved
9.1	13/10/2025	Update to DPIA to allow for sharing to appropriate organisations
10.0	13/10/2025	Final Updated Approved
10.1	10/11/2025	Update to DPIA
11.0	10/11/2025	Final Updated Approved

## Reviewers

**Redaction Rationale** – The information above for 'Information Asset/Product Owner' and 'Author(s)' has been redacted as this includes personal information, this has been completed in line with Section 40 (2) of the Freedom of Information Act 2000.

This document must be reviewed by the following people:

Reviewer name	Title / Responsibility	Date	Version
████████████████████	Deputy Director, IG Risk and Assurance	26/07/2024	0.3

[REDACTED]	Deputy Director, IG Risk and Assurance	01/08/2024	0.6
[REDACTED]	Head of IG - FDP	15/10/2024	2.0
[REDACTED]	Head of IG - FDP	28/10/2024	3.0
[REDACTED]	Head of IG – FDP	20/11/2024	4.0
[REDACTED]	Head of IG – FDP	27/11/2024	4.1
[REDACTED]	Head of IG – FDP	18/02/2025	5.1
[REDACTED]	Head of IG - FDP	04/04/2025	7.0
[REDACTED]	Head of IG - FDP	15/05/2025	7.1
[REDACTED]	Head of IG - FDP	28/05/2025	8.1
[REDACTED]	Head of IG - FDP	13/10/2025	9.1
[REDACTED]	Head of IG - FDP	10/11/2025	10.1

## Approved by

*Redaction Rationale – The information above for 'Information Asset/Product Owner' and 'Author(s)' has been redacted as this includes personal information, this has been completed in line with Section 40 (2) of the Freedom of Information Act 2000.*

This document must be approved by the following people:

Name	Title / Responsibility	Date	Version
[REDACTED]	Deputy Director, IG Risk and Assurance	01/08/2024	0.7
[REDACTED]	Head of IG – FDP	04/02/2025	7.0
[REDACTED]	Head of IG - FDP	15/05/2025	8.0
[REDACTED]	Head of IG - FDP	28/05/2025	9.0
[REDACTED]	Head of IG - FDP	13/10/2025	10.0
[REDACTED]	Head of IG - FDP	10/11/2025	11.0

## Document Control:

The controlled copy of this document is maintained in the NHS England corporate network. Any copies of this document held outside of that area, in whatever format (e.g. paper, email attachment), are considered to have passed out of control and should be checked for currency and validity.

## Contents

<b>Purpose of this document</b>	<b>5</b>
<b>1. Consultation with Stakeholders about the Product</b>	<b>10</b>
<b>2. Data Flow Diagram</b>	<b>11</b>
<b>3. Description of the Processing</b>	<b>12</b>
<b>4. Purpose of Processing Personal Data for this Product</b>	<b>12</b>
<b>5. Identification of risks</b>	<b>15</b>

<b>6. Compliance with the Data Protection Principles - for Processing Personal Data only</b>	<b>17</b>
<b>7. Describe the legal basis for the Processing (collection, analysis or disclosure) of Data?</b>	<b>17</b>
<b>8. Demonstrate the fairness of the Processing</b>	<b>20</b>
<b>9. What steps have you taken to ensure individuals are informed about the ways in which their Personal Data is being used?</b>	<b>21</b>
<b>10. Is it necessary to collect and process all Data items?</b>	<b>21</b>
<b>11. Provide details of Processors who are Processing Personal Data in relation to this Product</b>	<b>24</b>
<b>12. Describe if Data is to be shared from the Product with other organisations and the arrangements in place for this</b>	<b>24</b>
<b>13. How long will the Data be retained?</b>	<b>25</b>
<b>14. How you will ensure Personal Data is accurate and if necessary, kept up to date</b>	<b>25</b>
<b>15. How are individuals made aware of their rights and what processes do you have in place to manage requests to exercise their rights?</b>	<b>25</b>
<b>16. What technical and organisational controls in relation to information security have been put in place for this Product?</b>	<b>26</b>
<b>17. In which country/territory will Data be stored or processed?</b>	<b>26</b>
<b>18. Do Opt Outs apply to the Processing?</b>	<b>26</b>
<b>19. Risk mitigations and residual risks</b>	<b>27</b>
<b>20. Actions</b>	<b>35</b>
<b>21. Completion and signatories</b>	<b>35</b>
<b>22. Summary of high residual risks</b>	<b>35</b>
<b>Annex 1: Defined terms and meaning</b>	<b>37</b>

---

## Purpose of this document

A Data Protection Impact Assessment (DPIA) is a useful tool to help NHS England demonstrate how we comply with data protection law.

DPIAs are also a legal requirement where the Processing of Personal Data is “*likely to result in a high risk to the rights and freedoms of individuals*”. If you are unsure whether a DPIA is necessary, you should complete a DPIA screening questionnaire to assess whether the Processing you are carrying out is regarded as high risk.

Generally, a DPIA will not be required when Processing Operational Data which is not about individuals. However, a DPIA may be required when Processing Aggregated Data which has been produced from Personal Data, in order to provide assurance that the Aggregated Data is no longer Personal Data

By completing a DPIA you can systematically analyse your Processing to demonstrate how you will comply with data protection law and in doing so identify and minimise data protection risks.

### Defined Terms used in this DPIA

Defined terms are used in this DPIA where they are capitalised. When drafting the DPIA, those defined terms should be used for consistency and clarity. The defined terms and their meanings are set out in [Annex 1](#). Not all terms in Annex 1 may be used in the DPIA.

### Standard wording in this DPIA

Standard wording has been suggested in certain parts of this DPIA and highlighted yellow with square brackets around the text. You should select the wording that reflects the Processing of Data for the specific Product you are assessing and remove the square brackets, highlighting and wording you do not need to use eg:

- [For Data ingested into the FDP to create the Product]
- [For Data ingested into the Product to create the Product]

You would amend this where Data is ingested into the Product as follows:

- {For Data ingested into the FDP to create the Product}
- ~~[For Data ingested into the Product to create the Product]~~

## The aims of the Federated Data Platform (FDP)

Every day, NHS staff and clinicians are delivering care in new and innovative ways, achieving better outcomes for patients, and driving efficiency. Scaling and sharing these innovations across the health and care system in England is a key challenge for the NHS.

Harnessing the power of digital, Data and technology is the key to recovering from the pandemic, addressing longer-term challenges, and delivering services in new and more sustainable ways.

The future of our NHS depends on improving how we use Data to:

- care for our patients;
- improve population health;
- plan and improve services; and
- find new ways to deliver services.

## **The Federated Data Platform (FDP)**

A 'Data platform' refers to software which will enable NHS organisations to bring together Data – currently stored in separate systems – to support staff to access the information they need in one safe and secure environment so that they are better able to coordinate, plan and deliver high quality care.

A 'federated' Data platform means that every hospital trust and integrated care board (ICB) (on behalf of the integrated care system (ICS)) will have their own platform which can connect and collaborate with other Data platforms as a "federation" making it easier for health and care organisations to work together.

A digitised, connected NHS can deliver services more effectively and efficiently, with people at the centre, leading to:

### **1. Better outcomes and experience for people**

A more efficient NHS ultimately means a better service for patients, reduced waiting times and more timely treatment. The platform will provide ICBs with the insights they need to understand the current and future needs of their populations so they can tailor early preventative interventions and target health and care support. Patients will have more flexibility and choice about how and where they access services and receive care, helping them to stay healthy for longer.

### **2. Better experience for staff**

NHS staff will be able to access the information they need in one secure place. This reduces the time they spend chasing referrals, scheduling appointments, and waiting for test results and allows them to work more flexibly to deliver high quality care for their patients.

### **3. Connecting the NHS**

The connectivity of the platforms is extremely important as it will enable us to rapidly scale and share tools and applications that have been developed at a local level – in a secure way – supporting levelling up and reducing variation across England.

Federation means that each Trust and ICB has a separate Instance of the platform for which they are the Controller. Access for each Instance will be governed and managed by each individual organisation.


We want the NHS to be the best insight-driven health and care system in the world. This software will provide the foundation to improve the way that Data is managed and used across the NHS in England to transform services and save lives.

The FDP will not only provide the cutting-edge software to Trusts and ICBs to continue to innovate but the connectivity will enable NHS England (NHSE) to rapidly scale and share innovative solutions that directly addresses the challenges most pressing for the NHS. This will transform the way the NHS delivers its services enabling organisations to communicate and collaborate more effectively and provide better care for patients.

## **The 'Product' Data Protection Impact Assessment (DPIA)**

As part of the roll out of FDP, NHS England wants to enable Trusts and ICBs to use standard FDP Products as this will reduce burden for those organisations in creating their own analytical tools and will provide a consistent approach to how Data is used in relation to the five use cases and capabilities as shown in the diagram below.

A Product DPIA is part of a suite of DPIAs for FDP that sit under the overarching FDP DPIA and provide a mechanism for assessing data protection compliance at a detailed Product level. NHS England teams have created template Product DPIAs to help NHS England, NHS Trusts and ICBs comply with UK GDPR and the FDP IG Framework.



Key information about the Product
<b>Purpose of the Product - Overview</b>
<p>The National Vaccination Programme Reporting Product within FDP is a collection of operational reports based on Pseudonymised Data and Aggregated Data within FDP. This function allows National and Regional teams to report and monitor the vaccination and immunisation services in place and solely supports the vaccination programmes. Any additional use of this reporting Product would require this DPIA to be updated and reapproved.</p> <p><b>09/10/2024</b></p> <p>Update to DPIA to include the ingestion of Maternity Datasets and linkage to vaccination Datasets</p> <p><b>28/10/2024 Update</b></p> <p>Aggregated reports relating to Care Homes will be created utilising this tool and shared with the wider system.</p> <p><b>20/11/2024 Update</b></p> <p>Inclusion of historic and live invite information Data for eligible population cohorts for future vaccination campaigns.</p> <p><b>27/11/2024 Update</b></p> <p>This Product will now be made available to the NHS National Booking Service (NBS) to enable more cohesive response to the demand for RSV vaccination appointments.</p> <p><b>18/02/2025 Update</b></p> <p>Further update to the Product to reflect the name change from Contour Reporting to National Vaccination Programme Reporting. This update also include the addition of Pertussis, (also know as whooping cough) which can be serious for babies and may lead to complications, resulting in</p>

hospitalisation and even death. Babies can be protected against whooping cough through maternal vaccination during pregnancy.

#### **Update April 2025:**

NHS England is committed to the elimination of cervical cancer by 2040 and HPV vaccination is the key action to achieve this aim ([NHS England » Cervical cancer elimination by 2040 – plan for England](#)). The HPV vaccine prevents invasive strains of the virus, known to cause almost all cervical cancers, as well as some mouth and throat cancers. It is given to both girls and boys in secondary school to protect them against catching the HPV infection and developing into pre-cancerous and cancer cells. To eliminate cervical cancer by 2040, the NHS needs to ensure as many people as possible are being vaccinated against HPV.

The dataset laid out further in this DPIA does not change there is simply the addition of the HPV vaccine collection.

#### **Update May 2025:**

Update to DPIA to add local authority information to each school in the school reference data so that users can filter on these in reports. This is the addition of Aggregated Date from the below link;

<https://get-information-schools.service.gov.uk/Downloads>

#### **Update May 2025**

Requests have been made to allow further Operational Data to be ingested into the Product and be extracted from the Product for sharing this is covered below;

- Access and Inequalities funding data to be ingested into the Product in Operational form. This is to allow the tracking the spend of the Access and Inequalities for the financial year, this is crucial to allow analysis of this spend.
- The extraction of Data from this Product to allow this to be used for Data publication, FOI requests and internal NHS England requests, this will be in Aggregate form.
- The extraction of Oasis Datasets to allow analysis to be completed on this Operational and Aggregate Data in Power BI.

None of the Data in this update include Directly Identifiable Personal Data or Pseudonymised Data, this will be completed for only Anonymised, Aggregated or Operational Data.

#### **Update October 2025**

An update to this DPIA has been requested to allow region and regional organisations, to access Aggregate Data at a National level.

#### **Update November 2025**

There have been a couple of minor updates to the DPIA detailed below;

- MMRV (Measles, Mumps, Rubella and Varicella) vaccine is being introduced in January 2026 to replace the MMR vaccine; both vaccines will be in use initially with MMR being phased out over time, so in this document MMR has been replaced with MMR/MMRV
- From the CaaS dataflow detailed below, the information will also allow NHS England to report on vaccine uptake for people with a learning disability.

Local or National Product		
Local	<input type="checkbox"/>	National <input checked="" type="checkbox"/>
Product falls under the following Use Case(s)		
Care co-ordination	<input type="checkbox"/>	To ensure that health and care organisations all have access to the information they need to support the patient, enabling care to be coordinated across NHS services.
Elective Recovery	<input type="checkbox"/>	To get patients treated as quickly as possible, reducing the backlog of people waiting for appointments or treatments, including maximising capacity, supporting patient readiness and using innovation to streamline care.
Vaccination and Immunisation:	<input checked="" type="checkbox"/>	To ensure that there is fair and equal access, and uptake of vaccinations across different communities.
Population Health Management	<input type="checkbox"/>	To help local trusts, Integrated Care Boards (on behalf of the integrated care systems) and NHS England proactively plan services that meet the needs of their population.
Supply Chain	<input type="checkbox"/>	To help the NHS put resources where they are needed most and buy smarter so that we get the best value for money.
Categorisation of the Data used to create the Product		How the different Categories of Data are used in relation to the Product
Directly Identifiable Personal Data	<input type="checkbox"/>	
Pseudonymised Data	<input checked="" type="checkbox"/>	For Data ingested into the FDP to create the Product For Data ingested into the Product to create the Product
Anonymised Data	<input type="checkbox"/>	
Aggregated Data	<input checked="" type="checkbox"/>	For Data displayed or shared with users of the Product
Operational Data	<input type="checkbox"/>	
Type of Data used in the Product		
No Personal Data	<input type="checkbox"/>	

Personal Data	<input checked="" type="checkbox"/>	For Data ingested into the FDP to create the Product For Data ingested into the Product to create the Product For Data displayed or shared with users of the Product
Special Category Personal Data	<input checked="" type="checkbox"/>	For Data ingested into the FDP to create the Product For Data ingested into the Product to create the Product For Data displayed or shared with users of the Product

The Product DPIAs describe:

- the purpose for the creation of the Product;
- the Data which has been processed to create the Product. Where Aggregated Data is ingested into FDP, a DPIA is still carried out to provide assurance that the Aggregated Data is not Personal Data;
- the supporting legal basis for the collection, analysis and sharing of that Data;
- the Data flows which support the creation of the Product, and;
- the risks associated with the Processing of the Data and how they have been mitigated.

### National Product DPIAs

The Products described in the national Product DPIAs relate to NHS England’s use of the Product and related Data in the national Instance of the platform, and therefore all risks and mitigations of those risks contained within the DPIA are only applicable to NHS England.

### Local Product DPIAs

The Products described in the template local Product DPIAs relate to an NHS Trust or ICB use of the Product and related Data in a local Instance of the platform, and therefore all risks, and mitigations of those risks, contained within the DPIA are only applicable to Trusts and ICBs.


NHS Trusts and ICBs who use the Products made available to them are responsible for adopting and updating the template local Product DPIA or producing their own DPIA to reflect their specific use of the Product and to assess any specific risks relating to their organisation’s use of the Product.

## 1. Consultation with Stakeholders about the Product

<p>Informal consultation with users of the existing Foundry versions of this Product which was initially named Contour reports.</p> <p>All users agree that these reports and the information within them are vital for the management and delivery of seasonal and year-round vaccination programmes. It would not be possible to effectively manage all the different operational aspects of these programmes without the detailed (aggregated) information contained in the reports.</p> <p>Because all the data presented is aggregated there have been no concerns expressed about possible identification or other privacy concerns.</p>
--

## 2. Data Flow Diagram


### Flu / COVID / MMR/MMRV Vaccination Data / Respiratory Syncytial Virus (RSV) / Maternity Data Set / Pertussis / HPV



#### 27/11/2024 Update

This Product will now be made available to the NHS National Booking Service (NBS) to enable more cohesive response to the demand for RSV vaccination appointments.

#### Polio and MPOX



### 3. Description of the Processing

#### **Nature and scope of the processing:**

The scope of this DPIA is in relation to the processing of Data in creating National Vaccination Programme Reports which present solely Aggregate Data.

The Data processed for the Product is either ingested into FDP in Pseudonymised format or Aggregate format, this is set out below.

#### **Pseudonymised Data**

The Pseudonymised Data which has been processed by NHS England as part of the Vaccination Programme Requirements is transferred from UDAL into FDP. The processing within the FDP Instance is to create Aggregated Data, from the combined Pseudonymised Datasets as listed below:

Processing and analysis take place at individual vaccination event level. Data is then aggregated before being surfaced in a Report. Aggregation views used in these reports include MMR/MMRV uptake at school level, COVID and Flu vaccine uptake for frontline healthcare workers at NHS Trust level, and co-administration of COVID and Flu vaccines at national, regional and ICB level. Low figures are suppressed to create the aggregate view.

#### **Aggregated Data**

The Aggregated Data which is processed by NHS England to create Aggregate Anonymised Reporting to facilitate the share of information across National and Regional teams. This allows the NHS organisations to priorities and dedicate services to allow the delivery of care.

#### **Context of the processing:**

Data from these different sources is used to give aggregate-level reporting on vaccination activity in the reports. These reports typically focus on a specific operational issue and give National, Regional and Local programme managers the details and information required to deliver improvements to vaccination uptake and coverage.

### 4. Purpose of Processing Personal Data for this Product

The key objectives of the Product are to:

- Manage and monitor the delivery of seasonal and year-round vaccination programmes;
- Provide 'live' vaccination event data to support performance management and reporting purposes.

Please see screenshots of typical reports at the end of the DPIA, noting that new National Vaccination Reports are constantly being requested and created to support the changing requirements and priorities of the different vaccination programmes.

Examples of Vaccination reports include:

### **Frontline Healthcare Worker uptake report**

- Trust-level information on eligible cohort size (using ESR data) and the numbers and percentage of those staff receiving Covid and flu vaccinations in the Autumn seasonal programmes.
- Aggregate views at national and regional view to allow benchmarking and comparisons, to facilitate performance management of Trusts.

### **Coadministration report**

- Detailed report combining vaccination event data for Covid and flu seasonal programmes, RSV and Maternity Data and Pertussis for targeted vaccination programmes;
- Analysis of coadministration (people receiving Covid and flu vaccinations at a single event, i.e. getting both jabs at the same vaccination site and at the same time);
- This is a key measure of efficiency, cost-saving and patient experience, and the report shows variation at regional and local level which can then be acted on to drive improvements.

### **MMR/MMRV Schools Report**

- MMR/MMRV coverage has huge variation across the country, and catch-up programmes need to be targeted to have maximum impact;
- This report shows vaccine coverage (number and proportion of children that have had zero, one or two MMR/MMRV jabs);
- Operational information is used to focus catch-up programmes administered by School Aged Immunisation Services (SAIS) providers at the schools where it will have the biggest impact.

### **RSV Report**

RSV is a major cause of respiratory illness, particularly dangerous for infants and the elderly. The virus can lead to bronchiolitis and pneumonia, requiring hospitalisation and intensive care in severe cases. The new vaccination programme is a proactive measure to mitigate these risks and enhance public health.

This is a UK-wide programme. The rollout will begin in September 2024 for England, Wales and Northern Ireland, and in August 2024 for Scotland.

These reports will be used in new national immunisation programmes for infants and older adults following advice from the independent JCVI.



**Primary Doses and Seasonal Doses for specific Conditions**

Parameters: Vaccine Region, Intervention, Vaccine ICs, Condition, Age

Definitions:

- total\_population: 1 those individuals that meet the eligibility criteria for latest season booster vaccination. (non-HealthBoard if they have declared at point of previous vaccination to be non-HealthBoard, where the vaccination was administered during the previous season).
- seasonal\_dose: total number of individuals that have had a seasonal dose this season
- seasonal\_update: seasonal dose this season (on or after 1st April 2024) / total\_population
- primary\_update: percentage of total\_population who have received a 1st dose at any time

Notes:

- 1st\_dose: total number of 1st doses administered to patients within the total\_population
- 2nd\_dose: total number of 2nd doses administered to patients within the total\_population
- 3rd\_dose: total number of 3rd doses administered to patients within the total\_population
- 4th\_dose: total number of 4th doses administered to patients within the total\_population
- 5th\_dose: total number of 5th doses administered to patients within the total\_population
- 6th\_dose: total number of 6th doses administered to patients within the total\_population
- 7th\_dose: total number of 7th doses administered to patients within the total\_population
- 8th\_dose: total number of 8th doses administered to patients within the total\_population
- 9th\_dose: total number of 9th doses administered to patients within the total\_population
- 10th\_dose: total number of 10th doses administered to patients within the total\_population

Regional and national totals

Condition	Vaccine_Region	total_population	Seasonal_dose	Seasonal_update	Primary_dose	Primary_update	1st_dose	2nd_dose	3rd_dose	4th_dose	5th_dose	6th_dose	7th_dose	8th_dose	9th_dose	10th_dose
1	East of England	61,207	50,762	83.09%	61,207	100.00%	61,207	61,207	0	0	0	0	0	0	0	0
2	West Midlands	36,863	31,671	85.92%	36,863	100.00%	36,863	36,863	0	0	0	0	0	0	0	0
3	West of England	73,336	61,680	84.11%	73,336	100.00%	73,336	73,336	0	0	0	0	0	0	0	0
4	South East and Wes...	73,888	61,680	83.47%	73,888	100.00%	73,888	73,888	0	0	0	0	0	0	0	0
5	North West	47,563	39,588	83.23%	47,563	100.00%	47,563	47,563	0	0	0	0	0	0	0	0
6	South East	40,719	33,888	83.23%	40,719	100.00%	40,719	40,719	0	0	0	0	0	0	0	0
7	South West	40,719	33,888	83.23%	40,719	100.00%	40,719	40,719	0	0	0	0	0	0	0	0
8	London	301,140	250,027	83.02%	301,140	100.00%	301,140	301,140	0	0	0	0	0	0	0	0

ICs view

Condition	Vaccine_Region	Vaccine_ICs	total_population	Seasonal_dose	Seasonal_update	Primary_dose	Primary_update	1st_dose	2nd_dose	3rd_dose	4th_dose	5th_dose	6th_dose	7th_dose	8th_dose	9th_dose	10th_dose
1	East of England	146 South East	11,262	9,356	83.09%	11,262	100.00%	11,262	11,262	0	0	0	0	0	0	0	0
2	West Midlands	146 South East	6,036	5,127	84.94%	6,036	100.00%	6,036	6,036	0	0	0	0	0	0	0	0
3	West of England	146 South East	12,036	10,027	83.32%	12,036	100.00%	12,036	12,036	0	0	0	0	0	0	0	0
4	South East and Wes...	146 South East	12,036	10,027	83.32%	12,036	100.00%	12,036	12,036	0	0	0	0	0	0	0	0
5	North West	146 South East	7,514	6,205	82.71%	7,514	100.00%	7,514	7,514	0	0	0	0	0	0	0	0
6	South East	146 South East	6,500	5,391	82.94%	6,500	100.00%	6,500	6,500	0	0	0	0	0	0	0	0
7	South West	146 South East	6,500	5,391	82.94%	6,500	100.00%	6,500	6,500	0	0	0	0	0	0	0	0
8	London	146 South East	45,719	38,027	83.20%	45,719	100.00%	45,719	45,719	0	0	0	0	0	0	0	0

ICs view

Condition	Vaccine_Region	Vaccine_ICs	total_population	Seasonal_dose	Seasonal_update	Primary_dose	Primary_update	1st_dose	2nd_dose	3rd_dose	4th_dose	5th_dose	6th_dose	7th_dose	8th_dose	9th_dose	10th_dose
1	East of England	146 South East	11,262	9,356	83.09%	11,262	100.00%	11,262	11,262	0	0	0	0	0	0	0	0
2	West Midlands	146 South East	6,036	5,127	84.94%	6,036	100.00%	6,036	6,036	0	0	0	0	0	0	0	0
3	West of England	146 South East	12,036	10,027	83.32%	12,036	100.00%	12,036	12,036	0	0	0	0	0	0	0	0
4	South East and Wes...	146 South East	12,036	10,027	83.32%	12,036	100.00%	12,036	12,036	0	0	0	0	0	0	0	0
5	North West	146 South East	7,514	6,205	82.71%	7,514	100.00%	7,514	7,514	0	0	0	0	0	0	0	0
6	South East	146 South East	6,500	5,391	82.94%	6,500	100.00%	6,500	6,500	0	0	0	0	0	0	0	0
7	South West	146 South East	6,500	5,391	82.94%	6,500	100.00%	6,500	6,500	0	0	0	0	0	0	0	0
8	London	146 South East	45,719	38,027	83.20%	45,719	100.00%	45,719	45,719	0	0	0	0	0	0	0	0

ICs view

Condition	Vaccine_Region	Vaccine_ICs	total_population	Seasonal_dose	Seasonal_update	Primary_dose	Primary_update	1st_dose	2nd_dose	3rd_dose	4th_dose	5th_dose	6th_dose	7th_dose	8th_dose	9th_dose	10th_dose
1	East of England	146 South East	11,262	9,356	83.09%	11,262	100.00%	11,262	11,262	0	0	0	0	0	0	0	0
2	West Midlands	146 South East	6,036	5,127	84.94%	6,036	100.00%	6,036	6,036	0	0	0	0	0	0	0	0
3	West of England	146 South East	12,036	10,027	83.32%	12,036	100.00%	12,036	12,036	0	0	0	0	0	0	0	0
4	South East and Wes...	146 South East	12,036	10,027	83.32%	12,036	100.00%	12,036	12,036	0	0	0	0	0	0	0	0
5	North West	146 South East	7,514	6,205	82.71%	7,514	100.00%	7,514	7,514	0	0	0	0	0	0	0	0
6	South East	146 South East	6,500	5,391	82.94%	6,500	100.00%	6,500	6,500	0	0	0	0	0	0	0	0
7	South West	146 South East	6,500	5,391	82.94%	6,500	100.00%	6,500	6,500	0	0	0	0	0	0	0	0
8	London	146 South East	45,719	38,027	83.20%	45,719	100.00%	45,719	45,719	0	0	0	0	0	0	0	0

## 5. Identification of risks

This section identifies inherent risks of your Data Processing and potential harm or damage that it might cause to individuals whether physical, emotional, moral, material or non-material e.g. inability to exercise rights; discrimination; loss of confidentiality; re-identification of pseudonymised Data, etc.

This section is used to detail the risks arising from the proposed Processing Data if there are no steps in place to mitigate the risks. The sections below will then set out the steps you will take to mitigate the risks followed by a second risk assessment which considers the residual risk once the mitigation steps are in place.

Risk No	<p><b>Describe source of the risk and nature of potential impact on individuals</b></p> <p><i>The highlighted text are the most identified risks in the programme. Please amend and delete as appropriate and add Product specific risks. If the Data being processed is Directly Identifiable Personal Data, the risks will be different from below and you should refer to this category of Data. If the Data being processed is only Aggregated Data, then most of the risks below, other than small number suppression, may not be relevant.</i></p>
1	There is a risk that Pseudonymised Data may be accidentally misused by those with access
2	There is a risk that Pseudonymised Data will be processed beyond the appropriate retention period
3	There is a risk that insufficient organisational measures are in place to ensure appropriate security of the Pseudonymised Data (e.g. policies, procedures, disciplinary controls)
4	There is a risk that insufficient technical measures are in place to ensure appropriate security of the Pseudonymised Data (e.g. encryption, access controls)
5	There is a risk that Pseudonymised Data could be deliberately manipulated by an internal bad actor in some way to re-identify individual people
7	There is a risk that insufficient testing has taken place to assess and improve the effectiveness of technical and organisational measures.
8	There is a risk of failure to provide appropriate transparency information to data subjects.
9	There is a risk that increased access to Special Category Personal Data is given to NHS England staff who would not normally access that Data within their role.
10	There is a risk that the platform becomes inaccessible to users which could cause delays in the management of patient care and availability of Data.
11	There is a risk that inadequate data quality in source IT systems results in errors, inconsistencies and missing information that could compromise the integrity and reliability of the Data in the Product.
12	There is a risk that users will attempt to access FDP and the Product from outside the UK, increasing the data security risk.
13	There is a risk that users will not have their permissions revoked when they leave their role/organisation.

## 6. Compliance with the Data Protection Principles - for Processing Personal Data only

Compliance with the Data Protection Principles in relation to the Processing of Personal Data, as set out in Article 5 of the UK General Data Protection Regulation, are addressed in this DPIA in the following sections:

Data Protection Principle	Section addressed in this DPIA
Lawfulness, fairness and transparency	Section 7 (Lawfulness); Section 8 (Fairness); Section 9 (Transparency) and 11 (Processors)
Purpose limitation	Section 4
Data minimisation	Section 10
Accuracy	Section 14
Storage limitation	Section 13
Integrity and confidentiality (security)	Section 12 & 16
Accountability	Accountability is addressed throughout the DPIA. In particular, Section 21 includes approval of the residual risks by the Information Asset Owner and on behalf of the SIRO.

## 7. Describe the legal basis for the Processing (collection, analysis or disclosure) of Data?

<p><b>Statutory authority:</b> This is for national Products only, please remove the Datasets which are not applicable and remove the highlight and/or amend as necessary.</p> <p>NHSE's various statutory authorities for collecting, Processing, analysing and sharing Data are set out in the table below.</p>			
<p><b>COVID and Flu / Pertussis / HPV</b></p> <p><i>(Pertussis only relies on the Citizens Vaccination Direction)</i></p>			
Source Dataset	Statutory Authority for collection of Data	Statutory Authority for Processing & Analysis of Data	Statutory Authority for sharing of Data
Ethnicity Data (which is derived from GP Data) – <b>Note, only used for COVID, this</b>	<a href="#">GPES Data for Pandemic Planning and Research (COVID-19) - NHS England Digital</a>	NHS England De-Identified Data Analytics and Publication	Health and Social Care Act 2012 s.261(5)(d) and s.13Z3 (e) and (f)

is not used for Flu.		Directions 2023	
Personal Demographic Data	Primary care registration management Directions 2018 - NHS England Digital	NHS England De-Identified Data Analytics and Publication Directions 2023	Health and Social Care Act 2012 s.261(5)(d) and s.13Z3 (e) and (f)
Citizen vaccination event data, booking data, invite data and cohort data	Permitted under <a href="#">The Health Service (Control of Patient Information) Regulations 2002 (legislation.gov.uk)</a>	NHS England De-Identified Data Analytics and Publication Directions 2023	Health and Social Care Act 2012 s.261(5)(d) and s.13Z3 (e) and (f)
ESR Workforce Dataset	Permitted under <a href="#">The Health Service (Control of Patient Information) Regulations 2002 (legislation.gov.uk)</a>	NHS England De-Identified Data Analytics and Publication Directions 2023	Health and Social Care Act 2012 s.261(5)(d) and s.13Z3 (e) and (f)
Maternity Dataset	Maternity Services Data Set - NHS England Digital	NHS England De-Identified Data Analytics and Publication Directions 2023	Health and Social Care Act 2012 s.261(5)(d) and s.13Z3 (e) and (f)
DfE Census Data	DfE NHS E DSA	NHS England De-Identified Data Analytics and Publication Directions 2023	Secretary of State described in sections 2, 2A, 2B and 12 of the NHS Act 2006, Chapter 41, Part 1, so as to provide or secure the provision of s.7A services.

## Additional Contour Reporting Dataset

### Legal basis under UK GDPR & Data Protection Act 2018 (DPA 2018):

#### Article 6 – Personal Data

- Article 6(1)(c) Processing is necessary for compliance with a legal obligation, where NHS England collects and analyses Data under the Directions listed above (**Legal Obligation**).

#### Article 9 – Special Category Personal Data

- Article 9(2)(g) Processing is necessary for reasons of substantial public interest, where NHS England is Processing under Legal Obligation under Direction or Public Task, (**Substantial public interest**), plus Schedule 1, Part 2, Paragraph 6 ‘*statutory etc and government purposes*’ of DPA 2018

#### Common Law Duty of Confidentiality

- **Legal obligation** – NHSE is required by law to process Confidential Patient Data it collects, Pseudonymises and analyses to create the Pseudonymised Data and Aggregated Data input and Aggregated Data output for the Product. This is required under legal directions referred to above and issued by the Secretary of State for Health and Social Care to NHSE under section 254 of the Health and Social Care Act 2012.

#### MMR/MMRV, Maternity and RSV Data

### Legal basis under UK GDPR & Data Protection Act 2018 (DPA 2018):

#### Article 6 – Personal data

- *Article 6 (1) (e) processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller by virtue of the statutory functions referred to above (**Public Task**).*

#### Article 9 – Special category personal data

- *Article 9 (2) (h) processing is necessary for medical diagnosis, the provision of health care, or the treatment or management of health care services and system (**Health Care**) plus Schedule 1, Part 1, Paragraph 2 ‘Health or social care purposes’ of DPA 2018*

#### Common Law Duty of Confidentiality

**Legal obligation** – The Health Service (Control of Patient Information) Regulations 2002 (“COPI Regulations”) were passed to ensure that there was clear authority for the processing of confidential patient information in certain circumstances. They suspend the duty of confidentiality where confidential patient information is being processed in the circumstances described in the Regulations – see Regulation 4.

#### Polio and MPox Data

The Data ingested into FDP is Aggregate

## 8. Demonstrate the fairness of the Processing

Fairness means that we should handle Personal Data in ways that people would reasonably expect and not use it in ways that have an unjustified adverse impact on them.

The Product will have its own transparency information which sets out why the Processing is fair in what it is intended to achieve to improve the care of patients. Further information is set out in section 9 below.

Regarding the impact on individuals, the purpose of the Products to provide operational management information to support delivery of seasonal and year-round vaccination programmes, some of which are targeted at specific cohorts of the most vulnerable individuals. The different reports provide detailed reporting and analysis on specific operational and clinical aspects of different vaccination programmes. They support near real-time reporting, so issues can be quickly identified and resolved, as well as day-to-day operational decisions which fall within vaccination and immunisations. The impact for individuals of NHS England Processing this Data is that, as an output, there will be an increase in the percentage of the population of England which is vaccinated. NHS England is Processing Data in the Product to enable the NHS to operate effectively and to benefit patient care.

Any potential adverse impact to individuals is also mitigated by the Data being processed for this Product having been Pseudonymised and Aggregated before it is used and rendered Anonymous Aggregated Data when it is shared with users.

## 9. What steps have you taken to ensure individuals are informed about the ways in which their Personal Data is being used?

There is a range of information available on the NHS England website about FDP and how it works. This is Level 1 Transparency information.


There is a general FDP Privacy Notice which has been published via the NHS England webpages which also explains what FDP is and how it works in more detail. This is Level 2. It has a layered approach which has further detail in Level 3.

[NHS England » NHS Federated Data Platform privacy notice](#)

There is also a privacy notice specifically for this Product at Level 4 available via this link:

[NHS England » FDP products and product privacy notices](#)

### FDP Programme – Privacy Notice and Transparency Information Suggested Approach based on User Research



## 10. Is it necessary to collect and process all Data items?

Please see the detailed Data Specification below which identifies the source Datasets and specific Data items:

<b>Data Categories</b> [Information relating to the individual's]	<b>Yes/No</b>	<b>Justify</b> [there must be justification for Processing the Data items. Consider which items you could remove, without compromising the purpose for Processing]
<b>Personal Data</b>		
Name	No	
Address	No	
Postcode	Yes	The outward part of the individual's postcode only.  The individual's postcode is divided into two parts (outward & inward) separated by a single space, e.g. EC1A 1BB, only the outward part is to be provided.

<b>Data Categories</b> [Information relating to the individual's]	<b>Yes/No</b>	<b>Justify</b> [there must be justification for Processing the Data items. Consider which items you could remove, without compromising the purpose for Processing]
Date of Birth	No	
Age	Yes	Age of the individual on 31st March 2021. Note: The age will be calculated from the 31-Mar-2021
Sex	No	
Marital Status	No	
Gender	Yes	Due to the maternity Datasets Gender is collected by default
Living Habits	No	
Professional Training / Awards / Education	No	
Email Address	No	
Physical Description	No	
General Identifier e.g. NHS No	Yes	The NHS number is Pseudonymised
Home Phone Number	No	
Online Identifier e.g. IP Address/Event Logs	No	
Mobile Phone / Device No / IMEI No	No	
Location Data (Travel / GPS / GSM Data)	No	
Device MAC Address (Wireless Network Interface)	No	
Healthcare Worker / Social Care Worker status	Yes	A flag is added to ESR data by NHSBSA which is linked to an NHS number. This enables of monitoring of uptake of frontline healthcare workers and organisational targeted campaigns to be implemented.
<b>Special Category Data</b>		
Physical / Mental Health or Condition, Diagnosis/Treatment	Yes	SNOMED codes which indicate cohort eligibility, i.e Covid/Flu – morbid obesity, COVID – Chronic Respiratory disease etc.
Sexual Life / Orientation	No	
Religion or Other Beliefs	No	
Racial / Ethnic Origin	Yes	
Biometric Data (Fingerprints / Facial Recognition)	No	
Genetic Data	No	
<b>Criminal Conviction Data</b>		
Criminal convictions / alleged offences / outcomes / proceedings / sentences	No	
<b>Data specification</b>		
<b>Data Categories</b> [Information relating to the individual's]	<b>Yes/No</b>	<b>Justify</b> [there must be justification for Processing the Data items. Consider which items you could remove, without compromising the purpose for Processing]
<b>Personal Data</b>		
Pseudonymised NHS number	YES	Will be used to link the patient datasets prior to ingestion for Dashboard purposes
Action flag	YES	An action code to denote whether the record is to be added (ADD) to or updated (UPD) in the existing datasets.
Person ethnic category code	YES	Ethnicity category code for equality monitoring purposes
Vaccination Invite date	YES	For programme monitoring
Invite type - One of the following	YES	For programme monitoring
Cohort type	YES	For programme monitoring
Cohort description	YES	For programme monitoring

<b>Data Categories</b> [Information relating to the individual's]	<b>Yes/No</b>	<b>Justify</b> [there must be justification for Processing the Data items. Consider which items you could remove, without compromising the purpose for Processing]
Date and time vaccine administered	YES	For programme monitoring
Date and time vaccine recorded	YES	For programme monitoring
Professional Training / Awards / Education	Yes/No	
Site code type URI – describes the type of location code used e.g. ODS code or School Unique Reference Number (URN)	YES	For programme monitoring
Site code	YES	For programme monitoring
Vaccination product code (SNOMED-CT)	YES	For programme monitoring
Route of vaccination code (SNOMED-CT)	YES	For programme monitoring
Site of vaccination code (SNOMED-CT)	YES	For programme monitoring
Batch number	YES	For programme monitoring
Vaccine manufacturer	YES	For programme monitoring
Dose amount	YES	For programme monitoring
Not given	YES	For programme monitoring
Reason not given code (SNOMED-CT)	YES	For programme monitoring
Vaccination unique ID URI	YES	For uptake monitoring
Vaccination unique ID	YES	For uptake monitoring
Indication code (SNOMED-CT)	YES	For uptake monitoring
Location code	YES	For programme monitoring
Location code type URI	YES	For programme monitoring
Booking reference number	YES	For programme monitoring
Booking date and time	YES	For programme monitoring
Booking status	YES	For programme monitoring
Dose sequence number	YES	For programme monitoring
Vaccination type (SNOMED-CT)	YES	For programme monitoring
Self-declared cohort	YES	This will be used to specify the cohort to which individuals self-declare at the time of booking and is used for programme monitoring
· At Risk Individual		
· Health Worker		
· Unknown Unpaid Carer		
· Lives With Severely Immunosuppressed Individual		
· Severely Immunosuppressed Individual		
· Pregnant Individual		
Postcode (outward – first max 5 characters) e.g. EC1A	YES	For programme monitoring
EMPLOYER_ORG_CODE (from ESR)	YES	To enable reporting at organisational level
EMPLOYER_CODE (from ESR)	YES	To enable reporting at organisational level
EMPLOYEE_STAFF_GROUP (from ESR)	YES	To enable reporting by staff group
EMPLOYEE_OCCUPATION_CODE (from ESR)	YES	To enable reporting by occupational coding
FRONT_LINE (from ESR)	YES	Flag that indicates whether an individual is a frontline healthcare worker as per data held in ESR
ASSIGNMENT_STATUS (from ESR)	YES	The current assignment status of the staff member containing the values active or inactive – this is to ensure that those who have not been in active employment for a stated period are excluded from monitoring reports
ZERO_HOURS_STAFF (from ESR)	YES	To identify where the staff member is bank staff

<b>Data Categories</b> [Information relating to the individual's]	<b>Yes/No</b>	<b>Justify</b> [there must be justification for Processing the Data items. Consider which items you could remove, without compromising the purpose for Processing]
DATE_LAST_PAID (from ESR)	YES	So that we can account for employees with no active contract
DfE School unique reference number	YES	To map pupil to their school and facilitate schools-based coverage reporting

MSDS Data Specs

Additional Contour Datasets

**Update May 2025 – Additional Data;**

LA (code) LA (name) PreviousLA (code) PreviousLA (name)

## 11. Provide details of Processors who are Processing Personal Data in relation to this Product

- The Platform Contractor is a Processor acting on behalf of NHS England as a Controller in relation to Processing Pseudonymised Data held on the Platform, and which is used in the Product. The Platform Contract has required Data Processing provisions in it which meet the requirements of UK GDPR. In addition, a separate Data Processing Annex providing specific Processing instructions to the Platform Contractor for this Product will be issued. A copy of this Data Processing Annex is attached here:  
  
[National Vaccination Reporting – FDP Product Annex V3.0](#)

## 12. Describe if Data is to be shared from the Product with other organisations and the arrangements in place for this

Users of the Product are limited to:

- National, regional and local operational managers (ICBs and LAs) who have access to Aggregate Data and use the reports for day-to-day operational management and programme delivery
- National, regional and local NHS analysts who have access to person-level Pseudonymised Data and who use the data for creating bespoke reports for their operational teams
- Data can be shared with staff in other NHS organisations who are responsible for management or delivery of the specific vaccination programme.

Access is granted by the NHS England Vaccination Help Desk, with any request for access including the purpose, job role and the organisation. A successful request is provided with a purpose based access control that is required for their job role within their organisation.  
For further information on Purposed Based Access Control this can be located in the Overarching DPIA for FDP.

Access is reviewed through HR processes (people notified to the helpdesk as leavers through HR leavers forms or updates from colleagues have their access removed) and through user statistics data (dormant accounts have their access removed). This is carried out by the dedicated NHS England Vaccinations Help Desk. Access is revoked by the dedicated NHS England Vaccinations Help Desk.

### 13. How long will the Data be retained?

The Data will be kept in line with business requirements for the purposes of providing the Product. At the point that the Product is decommissioned, a further assessment will be undertaken to ascertain whether the Data can be destroyed, or a retention period agreed in line with the [NHS Records Management Code of Practice 2021](#).

### 14. How you will ensure Personal Data is accurate and if necessary, kept up to date

It is the responsibility of individual Data Controllers to ensure the accuracy of Personal Data. NHS England is not responsible for the accuracy of data sourced from GPs, Clinical providers through point of care systems, or NHS organisations using ESR. NHSE can amend Data which has been received through point of care systems should this be necessary. NHSE will also ensure that booking and invitation information is as accurate as possible both when collected at source and when provided for pseudonymisation and FDP ingestion. Through regional teams we work actively with local systems to ensure data accuracy and timely updating of information.

### 15. How are individuals made aware of their rights and what processes do you have in place to manage requests to exercise their rights?

General privacy information regarding the FDP is available in the FDP Privacy Notice on the NHSE website together with a Product specific Privacy Notice which sets out the rights which apply in relation to this Product.

The following rights under UK GDPR apply to the Processing of Pseudonymised Data to produce this Product:

- Right to be informed
- Right of access
- Right to rectify
- Right to object

Any requests would be handled by PTT's (Privacy Transparency and Trust) DPO & Trust Team in NHS England in accordance with standard processes.

## 16. What technical and organisational controls in relation to information security have been put in place for this Product?

The Overarching FDP DPIA (and where applicable, NHS-PET DPIA) sets out the technical and organisational controls for the Platform and the NHS-PET Solution.

### **Business Continuity Arrangements**

The information to allow direct care to take place is managed at a local level and Data will be accessed via the Point of Care systems, if there was a disruption to the Data Flow into FDP which is run nightly, the data will be flowed the following evening.

### **Specific Access controls for this Product**

A small number of NHSE and CSU Analysts, responsible for delivery of the National Vaccination Programme Reports, will have secure permission-based access to the Pseudonymised Data within FDP in order to manage the required dashboard aggregate-level visualisations for the users.

All potential users of the dashboard have to make a request for access via the dedicated NHS England Vaccinations Help Desk. There are Purpose Based Access Controls in place, to ensure each new requestor is given appropriate levels of access, for example restricting a user from a regional team to only see data for people resident in that region.

The support desk actively manages dormant accounts, removing access for users that have not viewed the dashboard in the last 6 months.

The Product Owner and IAO will be required to approve user access based on the Purpose Based Access Controls in place for the Product.

## 17. In which country/territory will Data be stored or processed?

All Processing of Data will be within the UK only, this is a contractual requirement and one of the key principles of the FDP IG Framework

## 18. Do Opt Outs apply to the Processing?

The National Data Opt Out policy does not apply to this Product as the collection and analysis of Data by NHS England to create the Product has been carried out under a legal obligation (the Legal Direction) and therefore the National Data Opt out does not apply.

Type 1 Opt Outs do not apply to this Product because the Datasets used to create the Product does not contain Confidential Patient Information that has been collected by NHS England from GP Practices.

## 19. Risk mitigations and residual risks

Section 4 of this DPIA sets out the inherent risks arising from the proposed Data Processing. This section summarises the steps to mitigate those risks (which are explained in detail above) and assesses the residual risks, i.e. the level of risk which remains once the mitigations are in place.

Against each risk you have identified at section 4, record the options/controls you have put in place to mitigate the risk and what impact this has had on the risk. Make an assessment as to the residual risk.

Also indicate who has approved the measure and confirm that responsibility and timescales for completion have been integrated back into the project plan.

Risk No	Risk	Steps to mitigate the risk	DPIA section in which step is described	Effect on risk. Tolerate / Terminate / Treat / Transfer	Likelihood of harm Remote / Possible / Probable	Severity of harm Minimal / Significant / Severe	Residual risk None / Low / Medium / High
1	Pseudonymised Data may be accidentally misused by those with access	<p>1. External suppliers are Processors on contracts with relevant security and data protection clauses contained within the agreements. Internal security and data protection processes are in place within NHS England.</p> <p>2. No external users have access to Pseudonymised Data through the dashboards in the Product. All internal users are required to sign security operating procedures that confirm their responsibilities to protect Data. Internal users are also subject to contractual confidentiality requirements.</p> <p>3. The download functionality of Data from the FDP is disabled by default, and access to this is controlled by the</p>	Section 12 & 16	Tolerate	Remote	Significant	Low

<b>Risk No</b>	<b>Risk</b>	<b>Steps to mitigate the risk</b>	<b>DPIA section in which step is described</b>	<b>Effect on risk. Tolerate / Terminate / Treat / Transfer</b>	<b>Likelihood of harm Remote / Possible / Probable</b>	<b>Severity of harm Minimal / Significant / Severe</b>	<b>Residual risk None / Low / Medium / High</b>
		Product Owner which ensures appropriate governance in in place. 4. Role Based Access Controls and Purpose Based Access Controls are in place to limit access to Pseudonymised Data to only those with a legitimate need eg developers of the Product. 5. The FDP access audit logs ensure that all access is logged and can be fully audited.					
2	Pseudonymised Data may be processed beyond the appropriate retention period.	1.Compliance with the Data Security Protection Toolkit (DSPT) requires Records Management policies to be in place. 2. The business area responsible for the Data have a Records Management Information Co-ordinator who will provide advice on how long Data should be retained at the point the dashboard is decommissioned.	Section 13	Tolerate	Remote	Minimal	Low
3	Insufficient organisational measures are in place to ensure appropriate security of the Personal Data (e.g. policies, procedures,	1.Appropriate organisational measures in relation to Data controls and governance are in place to ensure the security of the Data. 2. Organisational measures are adhered to across the Data platform. Any breaches are reported in line with these.	Set out in the Overarching FDP DPIA and Section 12 & 16 above	Tolerate	Remote	Minimal	Low

<b>Risk No</b>	<b>Risk</b>	<b>Steps to mitigate the risk</b>	<b>DPIA section in which step is described</b>	<b>Effect on risk.</b> Tolerate / Terminate / Treat / Transfer	<b>Likelihood of harm</b> Remote / Possible / Probable	<b>Severity of harm</b> Minimal / Significant / Severe	<b>Residual risk</b> None / Low / Medium / High
	disciplinary controls)	3. Role Based Access Controls and Purpose Based Access Controls are in place to limit access to Data.					
4	Insufficient technical measures are in place to ensure appropriate security of the Personal Data (e.g. encryption, access controls)	1. Data is encrypted in storage 2. All Data to and from the platform is encrypted in transit using at least TLS1.2 3. SLSP in place	Set out in the Overarching FDP DPIA and Section 12 & 16 above	Tolerate	Remote	Minimal	Low
5	Pseudonymised Data could be deliberately manipulated by an internal bad actor in some way to re-identify individual people	1. External suppliers are Processors on contracts with relevant security and data protection clauses contained within the agreements. Internal security and data protection processes are in place within NHS England. 2. Staff are trained and fully aware of their responsibilities when analysing Data to only use the minimum required for their purpose and that it is a criminal offence under the DPA 2018 to knowingly re-identify an individual	Set out in the Overarching FDP DPIA and Section 11, 12 & 16 above	Tolerate	Remote	Significant	Low

Risk No	Risk	Steps to mitigate the risk	DPIA section in which step is described	Effect on risk. Tolerate / Terminate / Treat / Transfer	Likelihood of harm Remote / Possible / Probable	Severity of harm Minimal / Significant / Severe	Residual risk None / Low / Medium / High
		<p>3. Contracts of employment and other organisational policies provide further safeguards against Data misuse</p> <p>4. Specific Data Processing instructions are provided to the Platform Contractor which limits their Processing of the Pseudonymised Data to this Product, and which prohibits any reidentification</p> <p>5. The download functionality of Data from the FDP is disabled by default, and access to this is controlled by the Product Owner which ensures appropriate governance in in place.</p>					
7	Insufficient testing has taken place to assess and improve the effectiveness of technical and organisational measures supporting the Product.	<p>1. Full details are described in the Overarching FDP DPIA.</p> <p>2. For national Products migrating from Foundry to FDP, there is no change in the Product, its operation or the technical measures supporting it. New governance processes for migrating existing Products have been put in place, including approval of relevant DPIAs by the DGG and the Deputy SIRO. This updated DPIA has also been put in place to assess the risks consistently across all national Products.</p>	Set out in the Overarching FDP DPIA and Section 3, 12 & 16 above	Tolerate	Remote	Minimal	Low

<b>Risk No</b>	<b>Risk</b>	<b>Steps to mitigate the risk</b>	<b>DPIA section in which step is described</b>	<b>Effect on risk. Tolerate / Terminate / Treat / Transfer</b>	<b>Likelihood of harm Remote / Possible / Probable</b>	<b>Severity of harm Minimal / Significant / Severe</b>	<b>Residual risk None / Low / Medium / High</b>
8	Subject Access Requests will not include a search of FDP or the Product, preventing individuals from having access to all Personal Data held about them	1. Existing internal NHSE procedures for managing DSARs have been updated to include consideration of any Personal Data held in FDP.	Section 15	Treat	Remote	Minimal	Low
9	Failure to provide appropriate transparency information to data subjects.	1. The NHSE General FDP Privacy Notice has been published and a separate Product Privacy Notice has been produced and will be published on NHS England's website with a link to it from the General FDP Privacy Notice.	Sections 8 and 9	Tolerate	Remote	Significant	Low
10	Increased access to Special Category Personal Data is given to staff who would not normally access that Data within their role.	1. Role Based and Purpose Based Access Controls are in place. [The addition of the Restricted View function to sit over the Purpose Based Access Controls ensures only those who need access to Special Category Personal Data are able to access this]. [2. The Data Processed to produce the Product has been Pseudonymised before being ingested into FDP.]	Section 12 & 16	Treat	Possible	Minimal	Low

<b>Risk No</b>	<b>Risk</b>	<b>Steps to mitigate the risk</b>	<b>DPIA section in which step is described</b>	<b>Effect on risk. Tolerate / Terminate / Treat / Transfer</b>	<b>Likelihood of harm Remote / Possible / Probable</b>	<b>Severity of harm Minimal / Significant / Severe</b>	<b>Residual risk None / Low / Medium / High</b>
		[3. Only analysts responsible for developing the Product have access to the Pseudonymised Data.]					
11	The platform becomes inaccessible to users which could cause [delays in the management of patient care][ and/or] [availability of Data].	1. The FDP Contractor is required to have Business Continuity Plans in place.  [2. The Product Owner has Business Continuity Plans in place which cover the inaccessibility/unavailability of the Product.]	Section 16	Tolerate	Remote	Significant	Low
12	Inadequate data quality in source IT systems results in errors, inconsistencies and missing information that could compromise the integrity and reliability of the Data in the Product.	1. The Product will only collect a subset of Personal Data from existing NHSE datasets.  2. It is our responsibility to ensure that all Data that is ingested into FDP for use in this Product is up to date and accurate for the purposes for which it is Processed within the Product. We will use our existing processes relating to the source datasets for maintaining accuracy.	Section 14	Tolerate	Remote	Significant	Low

Risk No	Risk	Steps to mitigate the risk	DPIA section in which step is described	Effect on risk. Tolerate / Terminate / Treat / Transfer	Likelihood of harm Remote / Possible / Probable	Severity of harm Minimal / Significant / Severe	Residual risk None / Low / Medium / High
13	Users will attempt to access FDP and the Product from outside the UK, increasing the data security risk.	<p>1. It is clearly articulated within the FDP IG Framework that no personal/patient data should leave or be accessible from outside of the UK without the express prior approval from the Data Governance Group.</p> <p>2. It is within the Platform Contract that no access to the system should take place from outside the UK.</p> <p>3. There are technical security measures in place to prevent access from outside the UK.</p>	Section 17	Treat	Remote	Minimal	Low
14	Users will not have their permissions revoked when they leave their role/ organisation and may continue to have access to Data they are no longer entitled to access	<p>1. As part of migrating national Products from Foundry to FDP, any users who have not accessed a migrating Product since January 2024 will have their access disabled. User accounts are also checked on a Product-by-Product basis with Product Owners regarding who should transition and if their access is still valid.</p> <p>2. Access is reviewed through HR processes (people notified to the helpdesk as leavers through HR</p>	Section 12 & 16	Treat	Remote	Significant	Low

Risk No	Risk	Steps to mitigate the risk	DPIA section in which step is described	Effect on risk. Tolerate / Terminate / Treat / Transfer	Likelihood of harm Remote / Possible / Probable	Severity of harm Minimal / Significant / Severe	Residual risk None / Low / Medium / High
		leavers forms or updates from colleagues have their access removed) and through user statistics data (dormant accounts have their access removed). This is carried out by the dedicated NHS England Vaccinations Help Desk. Access is revoked by the dedicated NHS England Vaccinations Help Desk.					

## 20. Actions

This section draws together all the actions that need to be taken in order to implement the risk mitigation steps that have been identified above, or any other actions required.

Action No	Actions required. (Date and responsibility for completion)	Risk No impacted by action	Action owner (Name and role)	Date to be completed
1	Expansion of the product should result in an update to this DPIA.	N/A	TBD	Ongoing at each change of the Product and update to this DPIA

## 21. Completion and signatories

The completed DPIA should be submitted to the NHSE Privacy Transparency and Trust IG Team via [england.pttigadvice@nhs.net](mailto:england.pttigadvice@nhs.net) (for review).

The IAO (Information Asset Owner) should keep the DPIA under review and ensure that it is updated if there are any changes (to the nature of the Processing, including new data items Processed, change of purpose, and/or system changes)

The DPIA accurately reflects the Processing and the residual risks have been approved by the Information Asset Owner:

### Information Asset Owner (IAO) Signature and Date

<b>Name</b>	Rebecca Llewellyn Federated Data Platform Programme Delivery Director Data Services Data and Analytics Transformation Directorate NHS England
<b>Signature</b>	Rebecca Llewellyn
<b>Date</b>	10/11/2025

**FOR DATA PROTECTION OFFICER USE ONLY**

## 22. Summary of high residual risks

Risk no.	High residual risk summary

--	--

**Summary of Data Protection Officer advice:**

<b>Name</b>	
<b>Signature</b>	
<b>Date</b>	
<b>Advice</b>	

**Where applicable: ICO (Information Commissioners Office) consultation outcome:**

<b>Name</b>	
<b>Signature</b>	
<b>Date</b>	
<b>Consultation outcome</b>	

**Next Steps:**

- **DPO to inform stakeholders of ICO consultation outcome**
- **IAO along with DPO and SIRO (Senior Information Risk Owner) to build action plan to align the Processing to ICO's decision**

## Annex 1: Defined terms and meaning

The following terms which may be used in this Document have the following meaning:

Defined Term	Meaning
<b>Aggregated Data</b>	Counts of Data presented as statistics so that Data cannot directly or indirectly identify an individual.
<b>Anonymisation</b>	Anonymisation involves the application of one or more anonymisation techniques to Personal Data. When done effectively, the anonymised information cannot be used by the user or recipient to identify an individual either directly or indirectly, taking into account all the means reasonably likely to be used by them. This is otherwise known as a state of being rendered anonymous in the hands of the user or recipient.
<b>Anonymised Data</b>	Personal Data that has undergone Anonymisation.
<b>Anonymous Data</b>	Anonymised Data, Aggregated Data and Operational Data.
<b>Approved Use Cases</b>	Means one of the five initial broad purposes for which Products in the Data Platform can be used as outlined in Part 1 of Schedule 2 (Approved Use Cases and Products) of the IG Framework, or any subsequent broad purpose agreed to be a use case through the Data Governance Group
<b>Categorisation of Data</b>	Means one of the following categories of Data: <ul style="list-style-type: none"> <li>• Directly Identifiable Personal Data</li> <li>• Pseudonymised Data</li> <li>• Anonymised Data,</li> <li>• Aggregated Data</li> <li>• Operational Data</li> </ul> <p>In the case of Directly Identifiable Personal Data or Pseudonymised Data this could be Personal Data or Special Category Personal Data.</p>
<b>Common Law Duty of Confidentiality</b>	The common law duty which arises when one person discloses information to another (e.g. patient to clinician) in circumstances where it is reasonable to expect that the information will be held in confidence.
<b>Confidential Patient Data</b>	Information about a patient which has been provided in circumstances where it is reasonable to expect that the information will be held in confidence, including Confidential Patient Information.

Defined Term	Meaning
<b>Confidential Patient Information</b>	Has the meaning given in section 251(10) and (11) of the NHS Act 2006. See Appendix 6 of the National Data Opt Out Operational Policy Guidance for more information <sup>1</sup>
<b>Controller</b>	Has the meaning given in UK GDPR being the natural or legal person, public authority, agency, or other body which, alone or jointly with others, determines the purposes and means of the Processing of Personal Data (subject to Section 6 of the Data Protection Act 2018)
<b>Data Governance Group</b>	Means a national group established by NHS England to provide oversight to the approach to Data Processing and sharing across all Instances of the Data Platform and NHS-PET which will include membership from across FDP User Organisations
<b>Data Platform or Platform</b>	The NHS Federated Data Platform
<b>Data Processing Annex</b>	The annex to the schedule containing Processing instructions in the form set out in the FDP Contracts.
<b>Data Protection Legislation</b>	The Data Protection Act 2018, UK GDPR as defined in and read in accordance with that Act, and all applicable data protection and privacy legislation, guidance, and codes of practice in force from time to time
<b>Direct Care</b>	A clinical, social, or public health activity concerned with the prevention, investigation and treatment of illness and the alleviation of suffering of individuals. It includes supporting individuals' ability to function and improve their participation in life and society. It includes the assurance of safe and high-quality care and treatment through local audit, the management of untoward or adverse incidents, person satisfaction including measurement of outcomes undertaken by one or more registered and regulated health or social care professionals and their team with whom the individual has a legitimate relationship for their care <sup>2</sup> .
<b>Directly Identifiable Personal Data</b>	Personal Data that can directly identify an individual.
<b>DPIA(s)</b>	Data Protection Impact Assessments in a form that meets the requirements of UK GDPR
<b>FDP</b>	Federated Data Platform
<b>FDP Contract</b>	The NHS-PET Contract and the Platform Contract
<b>FDP Contractor(s)</b>	The NHS-PET Contractor and/or the Platform Contractor

<sup>1</sup> <https://digital.nhs.uk/services/national-Data-opt-out/operational-policy-guidance-document/appendix-6-confidential-patient-information-cpi-definition>

<sup>2</sup> See the National Data Guardian Direct Care Decision Support Tool: [https://assets.publishing.service.gov.uk/media/5f2838d7d3bf7f1b1ea28d34/Direct\\_care\\_decision\\_support\\_tool.xlsx](https://assets.publishing.service.gov.uk/media/5f2838d7d3bf7f1b1ea28d34/Direct_care_decision_support_tool.xlsx)

Defined Term	Meaning
<b>FDP Programme</b>	The NHS England Programme responsible for the procurement and implementation of the FDP across the NHS
<b>FDP User Organisations</b>	NHS England, ICBs, NHS Trusts and other NHS Bodies (including a Commissioned Health Service Organisation) who wish to have an Instance of the Data Platform and who have entered into an MoU with NHS England. In the case of a Commissioned Health Service Organisation, the MoU is also to be entered into by the relevant NHS Body who has commissioned it
<b>General FDP Privacy Notice</b>	A privacy notice providing information on the Personal Data Processed in the Data Platform and by NHS-PET generally, including the Approved Use Cases for which Products will Process Personal Data
<b>ICB</b>	Integrated Care Board
<b>ICS</b>	Integrated Care System
<b>Incident</b>	An actual or suspected Security Breach or Data Loss Incident
<b>Instance</b>	A separate instance or instances of the Data Platform deployed into the technology infrastructure of an individual FDP User Organisation
<b>National Data Opt Out</b>	The Department of Health and Social Care's policy on the National Data Opt Out which applies to the use and disclosure of Confidential Patient Information for purposes beyond individual care across the health and adult social care system in England. See the National Data Opt Out Overview <sup>3</sup> and Operational Policy Guidance for more information <sup>4</sup>
<b>NHS-PET Contract</b>	The Contract between NHS England and the NHS-PET Contractor relating to the NHS-PET Solution dated 28 November 2023 as may be amended from time to time in accordance with its terms
<b>NHS-PET Contractor</b>	IQVIA Ltd
<b>NHS-PET Solution</b>	The privacy enhancing technology solution which records Data flows into the Data Platform and where required treats Data flows to de-identify them.
<b>Ontology</b>	Is a layer that sits on top of the digital assets (Datasets and models). The Ontology creates a complete picture by mapping Datasets and models used in Products to object types, properties, link types, and action types. The Ontology

<sup>3</sup> <https://digital.nhs.uk/services/national-data-opt-out/understanding-the-national-data-opt-out>

<sup>4</sup> <https://digital.nhs.uk/services/national-data-opt-out/operational-policy-guidance-document>

Defined Term	Meaning
	creates a real-life representation of Data, linking activity to places and to people.
<b>Operational Data</b>	Items of operational Data that do not relate to individuals eg stocks of medical supplies.
<b>Personal Data</b>	Has the meaning given in UK GDPR being any information relating to an identified or identifiable natural person ('Data subject'); an identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location Data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person . For the purposes of this DPIA this also includes information relating to deceased patients or service users. Personal Data can be Directly Identifiable Personal Data or Pseudonymised Data.
<b>Personal Data Breach</b>	Has the meaning given in UK GDPR being a breach of security leading to the accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to, Personal Data transmitted, stored, or otherwise Processed
<b>Platform Contract</b>	The agreement between NHS England and the Platform Contractor in relation to the Data Platform dated 21 November 2023 as may be amended from time to time in accordance with its terms
<b>Platform Contractor</b>	Palantir Technologies UK Ltd
<b>Product</b>	A product providing specific functionality enabling a solution to a business problem of an FDP User Organisation operating on the Data Platform.
<b>Product Privacy Notice</b>	A privacy notice providing information on the Personal Data Processed in the Data Platform and by NHS-PET in relation to each Product, including the purposes for which the Product Processes Personal Data
<b>Process or Processing</b>	Has the meaning given in UK GDPR being any operation or set of operations which is performed on Personal Data or on sets of Personal Data, whether or not by automated means, such as collection, recording, organisation, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, restriction, erasure, or destruction
<b>Processor</b>	Has the meaning given in UK GDPR being a natural or legal person, public authority, agency, or other body which Processes Personal Data on behalf of the Controller
<b>Programme</b>	The Programme to implement the Data Platform and NHS-PET across NHS England, NHS Trusts and ICBs

Defined Term	Meaning
<b>Pseudonymisation</b>	Has the meaning given in UK GDPR being the Processing of Personal Data in such a manner that the Personal Data can no longer be attributed to a specific individual without the use of additional information, provided that such additional information is kept separately and is subject to technical and organisational measures to ensure that the Personal Data are not attributed to an identified or identifiable natural person
<b>Pseudonymised Data</b>	Personal Data that has undergone Pseudonymisation
<b>Purpose Based Access Controls or PBAC</b>	Means user access to Data is based on the purpose for which an individual needs to use Data rather than their role alone as described more fully in Part 2 of Schedule 3
<b>Role Based Access Controls or RBAC</b>	Means user access is restricted to systems or Data based on their role within an organisation. The individual's role will determine what they can access as well as permission and privileges they will be granted as described more fully in Part 2 of Schedule 3
<b>Special Category Personal Data</b>	Means the special categories of Personal Data defined in Article 9(1) of UK GDPR being Personal Data revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union membership, and the Processing of genetic Data, biometric Data for the purpose of uniquely identifying a natural person, Data concerning health or Data concerning a natural person's sex life or sexual orientation.
<b>Transition Phase</b>	Is the first phase of rolling out the Data Platform which involves NHS England and local FDP User Organisations who currently use Products, moving their existing Products onto the new version of the software that is in the Data Platform. There is no change to the Data that is being processed, the purposes for which it is processed or the FDP User Organisations who are Processing the Data during the Transition Phase. The Transition Phase will start in March 2024 and is expected to run until May 2024.
<b>UK GDPR</b>	UK GDPR as defined in and read in accordance with the Data Protection Act 2018